{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:09:40Z","timestamp":1790352580875,"version":"4.1.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00520-026-11024-y","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:04:49Z","timestamp":1784588689000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world implementation of a standardized administration protocol for zolbetuximab-associated nausea and vomiting: a retrospective supportive-care cohort study"],"prefix":"10.1007","volume":"34","author":[{"given":"Tamotsu","family":"Sagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Umehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutaro","family":"Oiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Watabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Uesugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"11024_CR1","doi-asserted-by":"publisher","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA et al (2023) Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401(10389):1655\u20131668. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7","DOI":"10.1016\/S0140-6736(23)00620-7"},{"key":"11024_CR2","doi-asserted-by":"publisher","unstructured":"Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger PC, Ilson D et al (2023) Zolbetuximab plus capecitabine and oxaliplatin (CAPOX) in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 29:2133\u20132144. https:\/\/doi.org\/10.1038\/s41591-023-02465-7","DOI":"10.1038\/s41591-023-02465-7"},{"key":"11024_CR3","unstructured":"Japanese Society of Clinical Oncology (JSCO). Clinical Practice Guidelines for Antiemesis 2024. Available from: https:\/\/www.jsco.or.jp\/Portals\/0\/5_Guideline\/seitoyaku\/20240522v4.pdf. Accessed 18 July 2026"},{"issue":"1","key":"11024_CR4","first-page":"9","volume":"14","author":"DL Wong","year":"1988","unstructured":"Wong DL, Baker CM (1988) Pain in children: comparison of assessment scales. Pediatr Nurs 14(1):9\u201317","journal-title":"Pediatr Nurs"},{"key":"11024_CR5","unstructured":"National Cancer Institute (2017) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.\u00a0"},{"issue":"12","key":"11024_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17121996","volume":"17","author":"Y Narita","year":"2025","unstructured":"Narita Y, Mizuno T, Suda T et al (2025) Practical management of zolbetuximab administration: the Project VYLOY Initiative. Cancers (Basel) 17(12):1996. https:\/\/doi.org\/10.3390\/cancers17121996","journal-title":"Cancers (Basel)"},{"key":"11024_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105931","volume":"10","author":"K Shitara","year":"2025","unstructured":"Shitara K, Smyth E, Lordick F et al (2025) Impact and effective management of nausea\/vomiting on patients treated with zolbetuximab plus chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies. ESMO Open 10:105931. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105931","journal-title":"ESMO Open"},{"key":"11024_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105805","volume":"10","author":"K Yamamoto","year":"2025","unstructured":"Yamamoto K, Owaki Y, Nakayama I et al (2025) Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer. ESMO Open 10:105805. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105805","journal-title":"ESMO Open"},{"key":"11024_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2025.100257","author":"K Shimozaki","year":"2025","unstructured":"Shimozaki K, Ooki A, Fukuoka S et al (2025) Hypoalbuminemia during zolbetuximab plus chemotherapy for claudin 18.2-positive advanced gastric cancer: a need for caution? ESMO Gastrointestinal Oncology. https:\/\/doi.org\/10.1016\/j.esmogo.2025.100257","journal-title":"ESMO Gastrointestinal Oncology"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11024-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11024-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11024-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T14:55:48Z","timestamp":1786200948000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-11024-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["11024"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11024-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board of the National Hospital Organization Hokkaido Cancer Center (IRB No. 07-03).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"783"}}